Клиническое значение генетических мутаций при эпителиальных опухолях тимуса

Закрыть метаданные

Рекомендуем статьи по данной теме:

Лекарственная терапия при местнораспространенном и метастатическом немелкоклеточном раке легкого с МЕТ-мутацией: непрямое сравнение. Медицинские технологии. Оценка и выбор. 2024;(3):82-92

Новые методы патогенетической терапии миастении гравис. Журнал неврологии и психиатрии им. С.С. Корсакова. 2025;(1):31-38

Сравнительный анализ мутаций гена EGFR (20-й экзон) в синоназальных папилломах инвертированного и онкоцитарного типов. Архив патологии. 2025;(1):16-21

Эпителиальные опухоли тимуса составляют гетерогенную группу новообразований тимуса эпителиального происхождения с разнообразным клиническим поведением и лежащими в их основе молекулярно-генетическими особенностями. Карциномы вилочковой железы связаны с худшим прогнозом. Они встречаются значительно реже, чем тимомы, однако гораздо чаще являются инвазивными. Учитывая редкость и агрессивность карцином тимуса, оптимальное лечение этих новообразований по-прежнему остается нерешенной проблемой. Цель данного обзора — анализ исследований в области изучения генетического портрета опухолей тимуса и его клинического значения.

Ключевые слова:

эпителиальные опухоли тимуса

карцинома вилочковой железы

таргетная терапия

рецепторы тирозинкиназ

KIT

PDGFRA

EGFR

сунитиниб

иматиниб

сорафениб

VEGFR

регорафениб

ленватиниб

Авторы:

Сигал А.М.

ГАУЗ «Республиканский клинический онкологический диспансер им. проф. М.З. Сигала» Министерства здравоохранения Республики Татарстан

ORCID: 0000-0002-5918-4225

Ахметова О.В.

ФГАО ВО «Казанский (Приволжский) федеральный университет»

ORCID: 0000-0002-3477-0893

Саттарова Н.З.

ФГАО ВО «Казанский (Приволжский) федеральный университет»

ORCID: 0009-0000-9791-9619

Дата поступления:

15.01.2024

Дата принятия в печать:

03.06.2024

Список литературы:

Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg. 2003;76(3):878-884; discussion 884-885. https://doi.org/10.1016/s0003-4975(03)00555-1
Sakane T, Sakamoto Y, Masaki A, Murase T, Okuda K, Nakanishi R, Inagaki H. Mutation profile of thymic carcinoma and thymic neuroendocrine tumor by targeted next-generation sequencing. Clin Lung Cancer. 2021;22(2):92-99.e4. https://doi.org/10.1016/j.cllc.2020.11.010
Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol. 2004;202(3):375-381. https://doi.org/10.1002/path.1514
Bisagni G, Rossi G, Cavazza A, Sartori G, Gardini G, Boni C. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol. 2009;4(6):773-775. https://doi.org/10.1097/JTO.0b013e3181a52e25
Girard N, Shen R, Guo T, Zakowski MF, Heguy A, Riely GJ, Huang J, Lau C, Lash AE, Ladanyi M, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res. 2009;15(22):6790-6799. https://doi.org/10.1158/1078-0432.CCR-09-0644
Dişel U, Oztuzcu S, Beşen AA, Karadeniz C, Köse F, Sümbül AT, Sezer A, Nursal GN, Abalı H, Ozyılkan O. Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer. 2011;71(1):109-112. https://doi.org/10.1016/j.lungcan.2010.09.011
Buti S, Donini M, Sergio P, Garagnani L, Schirosi L, Passalacqua R, Rossi G. Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. J Clin Oncol. 2011;29(33):e803-e805. https://doi.org/10.1200/JCO.2011.36.6427
Nakagawa K, Matsuno Y, Kunitoh H, Maeshima A, Asamura H, Tsuchiya R. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest. 2005;128(1):140-144. https://doi.org/10.1378/chest.128.1.140
Ströbel P, Hartmann M, Jakob A, Mikesch K, Brink I, Dirnhofer S, Marx A. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med. 2004;350(25):2625-2626. https://doi.org/10.1056/NEJM200406173502523
Yoh K, Nishiwaki Y, Ishii G, Goto K, Kubota K, Ohmatsu H, Niho S, Nagai K, Saijo N. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer. 2008;62(3):316-320. https://doi.org/10.1016/j.lungcan.2008.03.013
Tsuchida M, Umezu H, Hashimoto T, Shinohara H, Koike T, Hosaka Y, Eimoto T, Hayashi JI. Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer. 2008;62(3):321-325. https://doi.org/10.1016/j.lungcan.2008.03.035
Terzi N, Yilmaz I, Batur S, Yegen G, Yol C, Arikan E, Oz A. C-KIT mutation in thymic carcinomas. Pol J Pathol. 2020;71(2):120-126. https://doi.org/10.5114/pjp.2020.97019
Ströbel P, Bargou R, Wolff A, Spitzer D, Manegold C, Dimitrakopoulou-Strauss A, Strauss L, Sauer C, Mayer F, Hohenberger P, et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer. 2010;103(2):196-200. https://doi.org/10.1038/sj.bjc.6605740
Lorusso PM, Eder JP. Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. Expert Opin Investig Drugs. 2008;17(7):1013-1028. https://doi.org/10.1517/13543784.17.7.1013
Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ, Lee S, Ling A, Spittler AJ, Carter CA, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015;16(2):177-186. https://doi.org/10.1016/S1470-2045(14)71181-7
Pagano M, Sierra NM, Panebianco M, Rossi G, Gnoni R, Bisagni G, Boni C. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations. Anticancer Res. 2014;34(9):5105-5110.
Neuhaus T, Luyken J. Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma. Target Oncol. 2012;7(4):247-251. https://doi.org/10.1007/s11523-012-0235-8
Catania C, Conforti F, Spitaleri G, Barberis M, Preda L, Noberasco C, Lazzari C, Toffalorio F, de Marinis F, Manzotti M, et al. Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. Onco Targets Ther. 2014;7:697-702. https://doi.org/10.2147/OTT.S58902
Raica M, Mogoantă L, Kondylis A, Cîmpean AM. Angiogenesis in the human thymoma assessed by subclassification of tumor-associated blood vessels and endothelial cells proliferation. Rom J Morphol Embryol. 2010;51(4):627-631.
Lattanzio R, La Sorda R, Facciolo F, Sioletic S, Lauriola L, Martucci R, Gallo E, Palmieri G, Evoli A, Alessandrini G, et al. Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study. Lung Cancer. 2014;85(2):191-196. https://doi.org/10.1016/j.lungcan.2014.05.010
Karube Y, Kobayashi S, Maeda S, Sado T, Ishihama H, Chida M. Tumor-related gene expression levels in thymic carcinoma and Type B3 thymoma. J Cardiothorac Surg. 2016;11(1):85. https://doi.org/10.1186/s13019-016-0468-1
Perrino M, De Pas T, Bozzarelli S, Giordano L, De Vincenzo F, Conforti F, Digiacomo N, Cordua N, D’Antonio F, Borea F, et al. Resound trial: a phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy. Cancer. 2022;128(4):719-726. https://doi.org/10.1002/cncr.33990
Sato J, Satouchi M, Itoh S, Okuma Y, Niho S, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, et al. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. Lancet Oncol. 2020;21(6):843-850. https://doi.org/10.1016/S1470-2045(20)30162-5
Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol. 2004;44:195-217. https://doi.org/10.1146/annurev.pharmtox.44.101802.121440
Syahruddin E, Zaini J, Sembiring R, Baginta R, Fadhillah MR, Noor DR. TP53 and EGFR mutational status in thymoma: a genetic sequencing study. Asian Pac J Cancer Prev. 2022;23(1):109-114. https://doi.org/10.31557/APJCP.2022.23.1.109
Aisner SC, Dahlberg S, Hameed MR, Ettinger DS, Schiller JH, Johnson DH, Aisner J, Loehrer PJ. Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study. J Thorac Oncol. 2010;5(6):885-892. https://doi.org/10.1097/JTO.0b013e3181d86a30
Scorsetti M, Leo F, Trama A, D’Angelillo R, Serpico D, Macerelli M, Zucali P, Gatta G, Garassino MC. Thymoma and thymic carcinomas. Crit Rev Oncol Hematol. 2016;99:332-350. https://doi.org/10.1016/j.critrevonc.2016.01.012
Zhan P, Chen X, Wu XY, Hou ZB, Qian Q, Zhang Y, Zou J, Zhang YQ, Wan MY, Wang JD, et al. Mutation analysis of the EGFR gene and its downstream signaling pathway in thymic carcinoma patients from a Chinese Han population. Clin Respir J. 2018;12(2):601-607. https://doi.org/10.1111/crj.12569
Sakane T, Murase T, Okuda K, Saida K, Masaki A, Yamada T, Saito Y, Nakanishi R, Inagaki H. A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3. Histopathology. 2019;75(5):755-766. https://doi.org/10.1111/his.13936
Arjonen A, Mäkelä R, Härmä V, Rintanen N, Kuopio T, Kononen J, Rantala JK. Image-based ex vivo drug screen to assess targeted therapies in recurrent thymoma. Lung Cancer. 2020;145:27-32. https://doi.org/10.1016/j.lungcan.2020.04.036
Farina G, Garassino MC, Gambacorta M, La Verde N, Gherardi G, Scanni A. Response of thymoma to cetuximab. Lancet Oncol. 2007;8(5):449-450. https://doi.org/10.1016/S1470-2045(07)70141-9
Yamaguchi H, Soda H, Kitazaki T, Tsukamoto K, Hayashi T, Kohno S. Thymic carcinoma with epidermal growth factor receptor gene mutations. Lung Cancer. 2006;52(2):261-262. https://doi.org/10.1016/j.lungcan.2006.01.009
Nakagiri T, Funaki S, Kadota Y, Takeuchi Y, Shiono H, Akashi A, Okumura M. Does gefitinib have effects on EGFR mutation-positive thymoma? Case report of thymoma recurrence. Ann Thorac Cardiovasc Surg. 2014;20(Suppl.):674-676. https://doi.org/10.5761/atcs.cr.13-00141
Brown LA. Successful use of erlotinib in treating recurrent thymic carcinoma: a case report. World J Oncol. 2013;4(4-5):214-216. https://doi.org/10.4021/wjon707w
Takahashi E, Koshiishi H, Takahashi M. [A response to erlotinib hydrochloride in the case of post-operative recurrent thymoma]. Gan To Kagaku Ryoho. 2011;38(12):2200-2201. (In Japanese).
Christodoulou C, Murray S, Dahabreh J, Petraki K, Nikolakopoulou A, Mavri A, Skarlos D. Response of malignant thymoma to erlotinib. Ann Oncol. 2008;19(7):1361-1362. https://doi.org/10.1093/annonc/mdn388
Bedano PM, Perkins S, Burns M, Kessler K, Nelson R, Schneider BP, Risley L, Dropcho S, Loehrer PJ. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol. 2008;26(15-suppl.):19087. https://doi.org/10.1200/jco.2008.26.15_suppl.19087
Pedersini R, Vattemi E, Lusso MR, Mazzoleni G, Ebner H, Graiff C. Erlotinib in advanced well-differentiated thymic carcinoma with overexpression of EGFR: a case report. Tumori. 2008;94(6):849-852. https://doi.org/10.1177/030089160809400613
Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res. 2007;13(19):5834-5840. https://doi.org/10.1158/1078-0432.CCR-07-1118
Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20(8):716-731. https://doi.org/10.1007/BF00181765
Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273-282. https://doi.org/10.1007/s002590050034
Lamberts SWJ, Hofland LJ. Anniversary review: Octreotide, 40 years later. Eur J Endocrinol. 2019;181(5):R173-R183. https://doi.org/10.1530/EJE-19-0074
Loehrer PJ Sr, Wang W, Johnson DH, Aisner SC, Ettinger DS.; Eastern Cooperative Oncology Group Phase II Trial. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol. 2004;22(2):293-299. https://doi.org/10.1200/JCO.2004.02.047
Palmieri G, Montella L, Martignetti A, Muto P, Di Vizio D, De Chiara A, Lastoria S. Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer. 2002;94(5):1414-1420. https://doi.org/10.1002/cncr.10374
Zucali PA, Petrini I, Lorenzi E, Merino M, Cao L, Di Tommaso L, Lee HS, Incarbone M, Walter BA, Simonelli M, et al. Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer. 2010;116(20):4686-4695. https://doi.org/10.1002/cncr.25367
Petrini I, Meltzer PS, Zucali PA, Luo J, Lee C, Santoro A, Lee HS, Killian KJ, Wang Y, Tsokos M, et al. Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. Cell Death Dis. 2012;3(7):e351. https://doi.org/10.1038/cddis.2012.92
Alberobello AT, Wang Y, Beerkens FJ, Conforti F, McCutcheon JN, Rao G, Raffeld M, Liu J, Rahhal R, Zhang YW, et al. PI3K as a potential therapeutic target in thymic epithelial tumors. J Thorac Oncol. 2016;11(8):1345-1356. https://doi.org/10.1016/j.jtho.2016.04.013
Zucali PA, De Pas T, Palmieri G, Favaretto A, Chella A, Tiseo M, Caruso M, Simonelli M, Perrino M, De Vincenzo F, et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol. 2018;36(4):342-349. https://doi.org/10.1200/JCO.2017.74.4078

Закрыть метаданные